User login
More than a decade after receiving autologous chondrocyte implants for treatment of full-thickness chondral lesions of the knee, nearly 75% of patients reported continued improvement or stability at their last follow-up, and 90% said they would have the procedure again.
Patients had significant improvement over baseline by objective clinical measures, although there was a slight but significant decline in function from the first to second follow-up period, according to Dr. Haris S. Vasiliadis and colleagues from the University of Gothenburg (Sweden) and the University of Ioannina (Greece).
Neither concomitant injuries to the knee nor prior bone marrow–stimulating surgeries appeared to decrease the overall benefit of chondrocyte implantation at long-term follow-up, the investigators wrote (Osteoarthritis Cartilage 2010 May 5 [doi:10.1016/j.joca.2010.04.003]).
They assessed responses from 224 patients who were treated with ACI in 1988–1998. At intermediate follow-up, the Lysholm scores (on a 0- to 95-point scale, with higher scores equating with better function) had improved by a mean of 14.8 points, compared with baseline (P = .0003). The mean change over baseline at 10 years was a 10-point improvement (P = .0016). Brittberg-Peterson scores (on a 0- to 130-point scale, with 0 being no pain and best function) were significantly lower at final follow-up than at baseline (mean decrease, 14 points; P = .004).
The investigators said no financial support was provided for the study, and they had no conflicts of interest.
More than a decade after receiving autologous chondrocyte implants for treatment of full-thickness chondral lesions of the knee, nearly 75% of patients reported continued improvement or stability at their last follow-up, and 90% said they would have the procedure again.
Patients had significant improvement over baseline by objective clinical measures, although there was a slight but significant decline in function from the first to second follow-up period, according to Dr. Haris S. Vasiliadis and colleagues from the University of Gothenburg (Sweden) and the University of Ioannina (Greece).
Neither concomitant injuries to the knee nor prior bone marrow–stimulating surgeries appeared to decrease the overall benefit of chondrocyte implantation at long-term follow-up, the investigators wrote (Osteoarthritis Cartilage 2010 May 5 [doi:10.1016/j.joca.2010.04.003]).
They assessed responses from 224 patients who were treated with ACI in 1988–1998. At intermediate follow-up, the Lysholm scores (on a 0- to 95-point scale, with higher scores equating with better function) had improved by a mean of 14.8 points, compared with baseline (P = .0003). The mean change over baseline at 10 years was a 10-point improvement (P = .0016). Brittberg-Peterson scores (on a 0- to 130-point scale, with 0 being no pain and best function) were significantly lower at final follow-up than at baseline (mean decrease, 14 points; P = .004).
The investigators said no financial support was provided for the study, and they had no conflicts of interest.
More than a decade after receiving autologous chondrocyte implants for treatment of full-thickness chondral lesions of the knee, nearly 75% of patients reported continued improvement or stability at their last follow-up, and 90% said they would have the procedure again.
Patients had significant improvement over baseline by objective clinical measures, although there was a slight but significant decline in function from the first to second follow-up period, according to Dr. Haris S. Vasiliadis and colleagues from the University of Gothenburg (Sweden) and the University of Ioannina (Greece).
Neither concomitant injuries to the knee nor prior bone marrow–stimulating surgeries appeared to decrease the overall benefit of chondrocyte implantation at long-term follow-up, the investigators wrote (Osteoarthritis Cartilage 2010 May 5 [doi:10.1016/j.joca.2010.04.003]).
They assessed responses from 224 patients who were treated with ACI in 1988–1998. At intermediate follow-up, the Lysholm scores (on a 0- to 95-point scale, with higher scores equating with better function) had improved by a mean of 14.8 points, compared with baseline (P = .0003). The mean change over baseline at 10 years was a 10-point improvement (P = .0016). Brittberg-Peterson scores (on a 0- to 130-point scale, with 0 being no pain and best function) were significantly lower at final follow-up than at baseline (mean decrease, 14 points; P = .004).
The investigators said no financial support was provided for the study, and they had no conflicts of interest.